Spero Therapeutics
SPRO
Spero Therapeutics (SPRO) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.16
- EPS estimate
- −$0.17
- EPS surprise
- +5.88%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 12, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 12, 2026 | −$0.17 | −$0.16 | +5.88% | $0.00 | SEC |
| Q1 2026 | May 13, 2026 | −$0.18 | −$0.13 | +27.78% | $258,000.00 | SEC |
| Q4 2025 | Mar 26, 2026 | −$0.20 | $0.53 | +365.00% | $41.3M | SEC |
| Q3 2025 | Nov 13, 2025 | −$0.25 | −$0.13 | +48.00% | $5.4M | SEC |
| Q2 2025 | Aug 12, 2025 | −$0.38 | −$0.03 | +92.11% | $14.2M | SEC |
| Q1 2025 | May 13, 2025 | −$0.55 | −$0.25 | +54.55% | $5.9M | SEC |
| Q4 2024 | Mar 27, 2025 | −$0.31 | −$0.38 | −22.58% | $15.0M | SEC |
| Q3 2024 | Nov 14, 2024 | −$0.27 | −$0.32 | −20.75% | $13.5M | SEC |
| Q2 2024 | Aug 5, 2024 | −$0.38 | −$0.33 | +13.16% | $10.2M | SEC |
| Q1 2024 | May 15, 2024 | −$0.04 | −$0.24 | −454.27% | $9.3M | SEC |
| Q4 2023 | Mar 13, 2024 | −$0.10 | $0.96 | +1060.00% | $73.5M | SEC |
| Q3 2023 | Nov 13, 2023 | −$0.03 | −$0.06 | −100.00% | $25.5M | SEC |
| Q2 2023 | Aug 10, 2023 | −$0.34 | −$0.23 | +33.00% | $2.7M | SEC |
| Q1 2023 | May 11, 2023 | −$0.33 | −$0.25 | +24.99% | $2.1M | SEC |
| Q4 2022 | Mar 30, 2023 | −$0.35 | $0.55 | +255.68% | $47.4M | SEC |
| Q3 2022 | Nov 14, 2022 | −$0.30 | −$0.33 | −8.80% | $2.0M | SEC |
| Q2 2022 | Aug 10, 2022 | −$0.93 | −$0.87 | +6.12% | $2.0M | SEC |
| Q1 2022 | May 16, 2022 | −$0.93 | −$1.01 | −8.60% | $2.1M | SEC |
| Q4 2021 | Mar 31, 2022 | −$0.75 | −$0.90 | −20.40% | $2.7M | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.66 | −$0.70 | −5.53% | $3.1M | SEC |
Quarterly revenue
Frequently asked questions
When did Spero Therapeutics (SPRO) last report earnings?
Spero Therapeutics last reported on Aug 12, 2026, covering fiscal Q2 2026.
Did SPRO beat earnings estimates?
Yes. Spero Therapeutics reported EPS of −$0.16 for Q2 2026 against a −$0.17 estimate — a 5.88% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.